Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus
Keywords:
Cellular medicaments
Cell-based therapy
Clinical trials
Diabetes
Critical limb ischemia
Cost-effective
Publisher:
Frontiers Media SA
Note:
This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Citation:
Soria-Juan, B. (Bárbara); Escacena, N. (Natalia); Capilla-González, V. (Vivian); et al. "Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus". Frontiers in Immunology. 10 (1151), 2019,
Statistics and impact
0 citas en
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.